Treatment of Alopecia Areata with Tofacitinib – A Jak Inhibitor

Authors

  • Dr DEEPIKA UIKEY Assistant Professor Author
  • Dr. Himanshu kumar Senior Resident Author
  • Dr shanta passi Associate Professor Author
  • Dr ishita dani PG Resident, Department of Dermatology, venereology, and leprosy, ESIC medical college & hospital, Faridabad Author

DOI:

https://doi.org/10.21276/9yvhvs14

Keywords:

alopecia areata, tofacitinib, JAK inhibitors

Abstract

Alopecia areata is an autoimmune non-scarring hair loss with a lifetime prevalence of 2% characterized by patches of hair loss in normal hair bearing areas. Key pathogenic events involves attack on hair follicles by auto-reactive CD8- T cells and local secretion of interferon (IFN)-gamma and interleukin (IL)-15 which activate target immune cells via the janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling pathway.

We describe 10 patients to evaluate the efficacy of oral tofacitinib, a janus- kinase 1 and 3 inhibitor in the treatment of alopecia areata.

A prospective study was conducted wherein the participants were given tablet tofacitinib 5 mg twice a day for 6 months and followed up for next 6 months after completion of treatment.

The minimum and maximum SALT scores were 26 and 96 respectively , with the mean SALT score of 45. 4 out of 10 patients achieved a SALT score of 0 by the end of therapy , all with either patchy or alopecia totalis pattern of hair-loss. Participants responded markedly in the first 3 months of therapy with complete regrowth in 6 months.

Pathogenesis of alopecia areata is not yet clearly defined however, JAK inhibitors seem to show promising results. The aim of our study is to highlight that if used within 6 months and in certain types of alopecia areata there can be great results with JAK inhibitors, however the major drawback is relapse of disease after stopping the treatment.

Downloads

Download data is not yet available.

References

Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of

alopecia areata in Olmsted county, Minnesota, 1975 through 1989. MayoClin

Proc 1995; 70:628‑33

Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal

models illuminate autoimmune pathogenesis and novel immunotherapeutic

strategies. Autoimmun Rev. 2016; 15(7):726–735.

Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New

approaches, new findings, new treatments. J Dermatol Sci 2015; 78:11‑20.

Alopecia areata: a review of disease pathogenesis. Rajabi F, Drake LA, Senna

MM, Rezaei N Br J Dermatol. 2018;179(5):1033.

Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J

Investig Dermatol Symp Proc. 2003;8(2):188–194.

Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T

lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–

Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is

linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–

Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal

models illuminate autoimmune pathogenesis and novel immunotherapeutic

strategies. Autoimmun Rev. 2016; 15(7):726–735. [PubMed: 26971464]

Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe

alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol

;76:22e8.

Bansal A, Relhan V, et al. A cross-sectional study of the histopathology and

immunology of alopecia areata: Unearthing the role of the Janus kinase–signal

transducer and activator of transcription pathway. IJDVL 2019;85(5):455-461

-Xiu Dai, Chih-Chiang Chen. Tofacitinib therapy for children with severe

alopecia areata. JAAD 2019; 80(4):1164-1166.

Downloads

Published

02.10.2023

Issue

Section

ORIGINAL ARTICLES ~ Biochemistry

Similar Articles

1-10 of 16

You may also start an advanced similarity search for this article.